Stryker (SYK) Q1 2026 earnings review
Cyberattack Derails Q1, But Full-Year Targets Defy Gravity
Stryker’s multi-year streak of double-digit growth hit a brick wall in Q1 following a severe cyberattack in March. The disruption halted momentum instantly: organic revenue growth decelerated to 2.4% (from 11.0% in 25Q4). Because short-term costs are largely fixed, the sudden volume drop crushed operating leverage. Adjusted EPS fell 8.5% YoY to $2.60, and adjusted operating margins compressed by 180 basis points. Despite the Q1 crater, management maintained its aggressive FY26 guidance (8.0-9.5% organic growth). This signals absolute confidence that orders were delayed, not permanently lost. However, it mathematically requires a massive, flawless acceleration in the remaining three quarters to hit the targets.
🐂 Bull Case
The cyber incident is a one-time operational shock. By maintaining full-year guidance, management is confirming that the capital order book and underlying hospital demand remain fully intact.
Despite the chaos, the Vascular and Trauma & Extremities segments grew 10.5% and 6.8% organically, proving that high-priority clinical procedures powered through the IT disruptions.
🐻 Bear Case
Because Q1 fell so far behind, Q2-Q4 must now average roughly 11% organic growth and nearly 15% EPS growth. Any further macro friction or lingering remediation costs will cause a guidance miss.
Adjusted gross margin collapsed by 190 basis points YoY. Remediating the cyber incident while fighting lingering tariff costs will keep the P&L under intense pressure.
⚖️ Verdict: ⚪
Neutral. The maintained guidance is a massive show of confidence, but the math is unforgiving. Stryker needs a perfect execution record for the rest of 2026 to fill the Q1 hole.
Key Themes
Severe Margin Contraction
The sudden volume shock destroyed Stryker's operating leverage. Adjusted Gross Margin fell a staggering 190 basis points (from 65.5% in 25Q1 to 63.6% in 26Q1), and Adjusted Operating Margin dropped 180 bps to 21.1%. With fixed expenses staying high, the delayed revenue flowed directly to the bottom line as losses. Reversing this trend requires immediate volume recovery in Q2.
MedSurg Growth Engine Stalls
Management claims 'underlying business momentum remains strong,' but the segment data contradicts this optimism. The historically robust MedSurg division was crippled: Medical segment organic sales contracted 6.9%, and Endoscopy declined 1.2%. The outsized hit to these capital-heavy divisions suggests their sales and deployment motions are highly vulnerable to IT and billing outages.
Vascular Segment Powers Through
Vascular was the standout performer, growing 27.5% reported and 10.5% organically. Boosted by the 2024 Inari acquisition, this segment successfully insulated itself from the broader Q1 IT disruptions, validating Stryker's strategic push into the high-growth peripheral vascular market.
Ortho Tech Consolidation
Stryker reorganized its reporting, combining Mako robotics, enabling technologies, and power tools into the new 'Ortho Tech' unit. This segment grew 6.5% organically to $646M. Centralizing hardware and software simplifies the customer pitch and strengthens Stryker's grip on integrated Ambulatory Surgery Center (ASC) deployments.
Trauma & Extremities Maintains Momentum
Despite the Q1 chaos, Trauma & Extremities posted a solid 6.8% organic growth ($1.03B). This business has been consistently taking market share, driven by recent platform launches like the Pangea plating system, which continues to see robust adoption regardless of broader corporate headwinds.
Persistent Macro & Tariff Pressures
While the cyberattack dominated the quarter, underlying macro pressures remain. Stryker absorbed massive tariff headwinds (~$400M) in 2025. The 190 bps drop in Q1 gross margin suggests supply chain costs and geopolitical trade friction are still squeezing profitability heavily, even before cyber-remediation costs are tallied.
Other KPIs
Operating cash flow provided limited buffer in Q1. Combined with $1.0B used to pay down debt, total cash and equivalents dropped significantly from $4.01B at year-end to $2.88B. The balance sheet remains strong, but Q1 was a highly cash-consumptive quarter.
Reported revenue for Spinal Implants essentially zeroed out (down 98.9% YoY from $166M). This finalizes the divestiture transition of the U.S. Spinal Implants business, which mathematically dragged down reported Orthopaedics growth to +0.1%, masking the underlying +4.1% organic growth in the remaining core portfolio.
Guidance
Accelerating. With Q1 organic growth coming in at just 2.4%, hitting the 8.75% midpoint implies a steep acceleration to roughly 10.8% average organic growth for Q2-Q4. Management explicitly assumes the cyber-delayed orders will be rapidly fulfilled.
Accelerating. The $15.00 midpoint implies roughly 10% YoY growth for the full year. Given the 8.5% YoY contraction in Q1, EPS must surge by roughly 15% YoY in the remaining three quarters, requiring flawless execution and rapid margin recovery.
Key Questions
Revenue Recovery
How much of the Q1 revenue shortfall do you estimate is permanently lost to competitors versus simply delayed into the Q2 and Q3 order books?
MedSurg Vulnerability
What specific dynamics caused the Medical and Endoscopy divisions to contract organically, while Orthopaedics maintained growth through the cyber incident?
Lingering Cyber Costs
What are the expected ongoing costs associated with IT remediation and security upgrades, and are they fully factored into the maintained EPS guidance?
Gross Margin Contraction
How much of the 190 basis point adjusted gross margin contraction was driven strictly by volume deleverage versus underlying supply chain friction or tariff costs?